Autologous CD19-CD20-NKG2D-nsBicephali CAR-T cell therapy (Beijing Gao Boren Hospital)

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameAutologous CD19-CD20-NKG2D-nsBicephali CAR-T cell therapy (Beijing Gao Boren Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20NKG2D ligands
Therapy Area/IndicationsCentral Nervous System Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co Ltd
Inactive CompaniesN/A
Active IndicationsCentral Nervous System Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A